Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ATM |
Variant | I1294Nfs*8 |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | ATM I1294Nfs*8 indicates a shift in the reading frame starting at amino acid 1294 and terminating 8 residues downstream causing a premature truncation of the 3056 amino acid Atm protein (UniProt.org). I1294Nfs*8 has not been characterized, however, due to the effects of other truncation mutations downstream of I1294 (PMID: 16603769), is predicted to lead to a loss of Atm protein function. |
Associated Drug Resistance | |
Category Variants Paths |
ATM mutant ATM inact mut ATM I1294Nfs*8 |
Transcript | NM_000051.4 |
gDNA | chr11:g.108284360dupA |
cDNA | c.3880dupA |
Protein | p.I1294Nfs*8 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047426976.1 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_017017789.2 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_017017790.2 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
NM_000051.4 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_047426975.1 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
NM_001351834.1 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_017017790.3 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_047426981.1 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_017017792.2 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_011542840.4 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_005271562.6 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_006718843.5 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
NM_000051.3 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_006718843.4 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_011542843.3 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_005271562.5 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_011542840.3 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_011542843.2 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
XM_017017791.1 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
NM_001351834.2 | chr11:g.108284360dupA | c.3880dupA | p.I1294Nfs*8 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM I1294Nfs*8 ATM E2977Rfs*2 | colorectal adenocarcinoma | predicted - sensitive | Irinotecan + Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) and Camptosar (irinotecan) combination treatment resulted in decreased tumor markers and stable disease in the primary and metastatic tumors in a heavily pretreated patient with metastatic colorectal adenocarcinoma harboring ATM E2977Rfs*2, ATM I1294Nfs*8, and KRAS G13D, lasting at least 4 months (PMID: 35004311). | 35004311 |